ArticlePancreas1995
The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets.
Article in Pancreas, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02473809 (The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function
Who cites it
18 citing papers in PubMed.
- Trial
- Trial
- Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.The Journal of clinical investigation · 1998 · on this mapTrial
- Pancreatic β-cell heterogeneity in adult human islets and stem cell-derived islets.Cellular and molecular life sciences : CMLS · 2023Review
- Antidiabetic effect of an engineered bacteriumSynthetic and systems biotechnology · 2021Article
- Targeting lipid GPCRs to treat type 2 diabetes mellitus - progress and challenges.Nature reviews. Endocrinology · 2021Review
- Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism.Clinical medicine insights. Endocrinology and diabetes · 2020Review
- Glucagon-like peptide 1 (GLP-1).Molecular metabolism · 2019 · on this mapReview
- DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs.Frontiers in immunology · 2019Review
- GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type CaPhysiological reports · 2018Article
- A novel glucagon-related peptide (GCRP) and its receptor GCRPR account for coevolution of their family members in vertebrates.PloS one · 2013Article
- Delta cell secretory responses to insulin secretagogues are not mediated indirectly by insulin.Diabetologia · 2012Article
- Structural and molecular conservation of glucagon-like Peptide-1 and its receptor confers selective ligand-receptor interaction.Frontiers in endocrinology · 2012Article
- The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms.Diabetologia · 2007Article
- Mechanisms of action of glucagon-like peptide 1 in the pancreas.Pharmacology & therapeutics · 2007Review
- Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagon-like peptide-I (GLP-I) is a potent incretin hormone that is now considered as a new therapeutic tool in the treatment of diabetes mellitus. In this study we characterized the effects of GLP-I on peptide hormone release from isolated human pancreatic islets. GLP-I stimulated insulin release in the presence of 10 mM glucose (2.8 mM glucose, 100%; 10 mM glucose, 166%; 10 mM glucose + 10 nM GLP-I, 222%) but had only a weak insulinotropic effect (128%) at 2.8 mM glucose. Glucagon release was inhibited by 10 mM glucose (2.8 mM glucose, 100%; 10 mM glucose, 72%) and by 10 nM GLP-I at 2.8 mM glucose (67%). Somatostatin secretion was increased by 10 mM glucose (2.8 mM glucose, 100%; 10 mM glucose, 166%). GLP-I stimulated somatostatin release in the presence of 2.8 mM glucose (172%). Pancreatic polypeptide (PP) secretion was enhanced by 10 mM glucose (2.8 mM glucose, 100%; 10 mM glucose, 236%). GLP-I induced PP release only in the presence of 2.8 mM glucose (184%).
Indexed as
Identifiers
7479679What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.